CoChat
Sign Up
Cited by 144

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Biochemical Correction of X-CGD by a Novel Chimeric Promoter Regulating High Levels of Transgene Expression in Myeloid Cells

Santilli, Giorgia, Almarza, Elena, Brendel, Christian, Choi, Uimook, Beilin, Chiara, Blundell, Michael P, Haria, Sneha, Parsley, Kathryn L, Kinnon, Christine, Malech, Harry L, Bueren, Juan A, Grez, Manuel, Thrasher, Adrian J·2011·Molecular Therapy
DOI 10.1038/mt.2010.226
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/mt.2010.226

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 37

  1. Ryser, 2007, Gene therapy for chronic granulomatous disease, Expert Opin Biol Ther, 7, 1799, 10.1517/14712598.7.12.1799 · DOI
  2. Kang, 2010, Retrovirus gene therapy for X-linked chronic granulomatous disease can achieve stable long-term correction of oxidase activity in peripheral blood neutrophils, Blood, 115, 783, 10.1182/blood-2009-05-222760 · DOI
  3. Ott, 2006, Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertional activation of MDS1-EVI1, PRDM16 or SETBP1, Nat Med, 12, 401, 10.1038/nm1393 · DOI · Paper page
  4. Malech, 1997, Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease, Proc Natl Acad Sci USA, 94, 12133, 10.1073/pnas.94.22.12133 · DOI
  5. Stein, 2010, Genomic instability and myelodysplasia with monosomy 7 consequent to EVI1 activation after gene therapy for chronic granulomatous disease, Nat Med, 16, 198, 10.1038/nm.2088 · DOI · Paper page
  6. Cattoglio, 2007, Hot spots of retroviral integration in human CD34+ hematopoietic cells, Blood, 110, 1770, 10.1182/blood-2007-01-068759 · DOI
  7. Schröder, 2002, HIV-1 integration in the human genome favors active genes and local hotspots, Cell, 110, 521, 10.1016/S0092-8674(02)00864-4 · DOI · Paper page
  8. Montini, 2006, Hematopoietic stem cell gene transfer in a tumor-prone mouse model uncovers low genotoxicity of lentiviral vector integration, Nat Biotechnol, 24, 687, 10.1038/nbt1216 · DOI
  9. Modlich, 2009, Insertional transformation of hematopoietic cells by self-inactivating lentiviral and γ-retroviral vectors, Mol Ther, 17, 1919, 10.1038/mt.2009.179 · DOI · Paper page
  10. Dewald, 1975, Subcellular localization and heterogeneity of neutral proteases in neutrophilic polymorphonuclear leukocytes, J Exp Med, 141, 709, 10.1084/jem.141.4.709 · DOI
  11. Lennartsson, 2005, The proximal promoter of the human cathepsin G gene conferring myeloid-specific expression includes C/EBP, c-myb and PU.1 binding sites, Gene, 356, 193, 10.1016/j.gene.2005.05.004 · DOI
  12. Grisolano, 1997, Altered myeloid development and acute leukemia in transgenic mice expressing PML-RAR α under control of cathepsin G regulatory sequences, Blood, 89, 376, 10.1182/blood.V89.2.376 · DOI
  13. Ferrari, 1990, Differential effects of c-myb and c-fes antisense oligodeoxynucleotides on granulocytic differentiation of human myeloid leukemia HL60 cells, Cell Growth Differ, 1, 543
  14. Yu, 1989, K562 leukemia cells transfected with the human c-fes gene acquire the ability to undergo myeloid differentiation, J Biol Chem, 264, 10276, 10.1016/S0021-9258(18)81796-3 · DOI
  15. Heydemann, 2000, A minimal c-fes cassette directs myeloid-specific expression in transgenic mice, Blood, 96, 3040, 10.1182/blood.V96.9.3040 · DOI
  16. Heydemann, 1996, The myeloid-cell-specific c-fes promoter is regulated by Sp1, PU.1, and a novel transcription factor, Mol Cell Biol, 16, 1676, 10.1128/MCB.16.4.1676 · DOI · Paper page
  17. Sturrock, 2004, Human leukocyte elastase gene expression is regulated by PU.1 in conjunction with closely associated cytidine-rich and Myb binding sites, Biochim Biophys Acta, 1676, 104, 10.1016/j.bbaexp.2003.10.005 · DOI
  18. Borregaard, 2001, Regulation of human neutrophil granule protein expression, Curr Opin Hematol, 8, 23, 10.1097/00062752-200101000-00005 · DOI
  19. Björgvinsdóttir, 1997, Retroviral-mediated gene transfer of gp91phox into bone marrow cells rescues defect in host defense against Aspergillus fumigatus in murine X-linked chronic granulomatous disease, Blood, 89, 41, 10.1182/blood.V89.1.41 · DOI
  20. Dinauer, 2001, Variable correction of host defense following gene transfer and bone marrow transplantation in murine X-linked chronic granulomatous disease, Blood, 97, 3738, 10.1182/blood.V97.12.3738 · DOI
  21. Moreno-Carranza, 2009, Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells, Gene Ther, 16, 111, 10.1038/gt.2008.143 · DOI
  22. Skalnik, 1991, Targeting of transgene expression to monocyte/macrophages by the gp91-phox promoter and consequent histiocytic malignancies, Proc Natl Acad Sci USA, 88, 8505, 10.1073/pnas.88.19.8505 · DOI
  23. Bu-Ghanim, 1995, Molecular analysis in three cases of X91-variant chronic granulomatous disease, Blood, 86, 3575, 10.1182/blood.V86.9.3575.bloodjournal8693575 · DOI
  24. Defendi, 2009, A novel point mutation in the CYBB gene promoter leading to a rare X minus chronic granulomatous disease variant—impact on the microbicidal activity of neutrophils, Biochim Biophys Acta, 1792, 201, 10.1016/j.bbadis.2009.01.005 · DOI
  25. Plachetka, 2008, C/EBPβ induces chromatin opening at a cell-type-specific enhancer, Mol Cell Biol, 28, 2102, 10.1128/MCB.01943-07 · DOI
  26. Chayka, 2005, v-Myb mediates cooperation of a cell-specific enhancer with the mim-1 promoter, Mol Cell Biol, 25, 499, 10.1128/MCB.25.1.499-511.2005 · DOI
  27. Gewirtz, 1990, Molecular regulation of human megakaryocyte development, Int J Cell Cloning, 8, 267, 10.1002/stem.5530080411 · DOI
  28. Maly, 1989, Superoxide-dependent nitroblue tetrazolium reduction and expression of cytochrome b-245 components by human tonsillar B lymphocytes and B cell lines, J Immunol, 142, 1260, 10.4049/jimmunol.142.4.1260 · DOI
  29. Zhang, 2007, Lentiviral vectors containing an enhancer-less ubiquitously acting chromatin opening element (UCOE) provide highly reproducible and stable transgene expression in hematopoietic cells, Blood, 110, 1448, 10.1182/blood-2006-12-060814 · DOI
  30. Gruhne, 2009, The Epstein-Barr virus nuclear antigen-1 promotes genomic instability via induction of reactive oxygen species, Proc Natl Acad Sci USA, 106, 2313, 10.1073/pnas.0810619106 · DOI
  31. Sadat, 2003, Long-term high-level reconstitution of NADPH oxidase activity in murine X-linked chronic granulomatous disease using a bicistronic vector expressing gp91phox and a Delta LNGFR cell surface marker, Hum Gene Ther, 14, 651, 10.1089/104303403321618164 · DOI
  32. Brown, 2007, Endogenous microRNA can be broadly exploited to regulate transgene expression according to tissue, lineage and differentiation state, Nat Biotechnol, 25, 1457, 10.1038/nbt1372 · DOI
  33. Brown, 2009, Exploiting and antagonizing microRNA regulation for therapeutic and experimental applications, Nat Rev Genet, 10, 578, 10.1038/nrg2628 · DOI · Paper page
  34. Tucker, 1987, Characterization of a new human diploid myeloid leukemia cell line (PLB-985) with granulocytic and monocytic differentiating capacity, Blood, 70, 372, 10.1182/blood.V70.2.372.372 · DOI
  35. Dinauer, 1993, The respiratory burst oxidase and the molecular genetics of chronic granulomatous disease, Crit Rev Clin Lab Sci, 30, 329, 10.3109/10408369309082591 · DOI
  36. Roesler, 2002, Third-generation, self-inactivating gp91(phox) lentivector corrects the oxidase defect in NOD/SCID mouse-repopulating peripheral blood-mobilized CD34+ cells from patients with X-linked chronic granulomatous disease, Blood, 100, 4381, 10.1182/blood-2001-12-0165 · DOI
  37. Pick, 1986, Microassays for superoxide and hydrogen peroxide production and nitroblue tetrazolium reduction using an enzyme immunoassay microplate reader, Meth Enzymol, 132, 407, 10.1016/S0076-6879(86)32026-3 · DOI

Cited by

See all 144

Metadata

Authors
Santilli, G., Almarza, E., Brendel, C., Choi, U., Beilin, C., Blundell, M. P., Haria, S., Parsley, K. L., Kinnon, C., Malech, H. L., Bueren, J. A., Grez, M., & Thrasher, A. J.
Venue
Molecular Therapy
Publisher
Elsevier BV
Published
2011-01
Volume
19
Issue
1
Pages
122-132
ISSN
1525-0016
DOI
10.1038/mt.2010.226
Cited by
144
References
8
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review